Selected Financial Data
since 2005
Income Statement
Abiomed Inc., selected items from income statement, long-term trends
US$ in thousands
| 12 months ended: | Revenue | Income (loss) from operations | Net income (loss) |
|---|---|---|---|
| Mar 31, 2022 | 1,031,753) | 140,720) | 136,505) |
| Mar 31, 2021 | 847,522) | 229,557) | 225,525) |
| Mar 31, 2020 | 840,883) | 249,219) | 203,009) |
| Mar 31, 2019 | 769,432) | 224,812) | 259,016) |
| Mar 31, 2018 | 593,749) | 157,137) | 112,170) |
| Mar 31, 2017 | 445,304) | 90,138) | 52,116) |
| Mar 31, 2016 | 329,543) | 65,104) | 38,147) |
| Mar 31, 2015 | 230,311) | 28,666) | 113,688) |
| Mar 31, 2014 | 183,643) | 8,363) | 7,351) |
| Mar 31, 2013 | 158,124) | 16,543) | 15,014) |
| Mar 31, 2012 | 126,375) | 1,520) | 1,495) |
| Mar 31, 2011 | 101,151) | (11,185) | (11,755) |
| Mar 31, 2010 | 85,713) | (25,076) | (19,024) |
| Mar 31, 2009 | 73,210) | (29,518) | (31,597) |
| Mar 31, 2008 | 58,941) | (36,487) | (40,930) |
| Mar 31, 2007 | 50,649) | (28,511) | (27,881) |
| Mar 31, 2006 | 43,670) | (30,291) | (29,449) |
| Mar 31, 2005 | 38,216) | (3,253) | (2,342) |
Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31), 10-K (reporting date: 2016-03-31), 10-K (reporting date: 2015-03-31), 10-K (reporting date: 2014-03-31), 10-K (reporting date: 2013-03-31), 10-K (reporting date: 2012-03-31), 10-K (reporting date: 2011-03-31), 10-K (reporting date: 2010-03-31), 10-K (reporting date: 2009-03-31), 10-K (reporting date: 2008-03-31), 10-K (reporting date: 2007-03-31), 10-K (reporting date: 2006-03-31), 10-K (reporting date: 2005-03-31).
- Revenue
- The revenue demonstrates a consistent and significant upward trend over the observed period. Starting from approximately 38.2 million USD in 2005, the revenue grows steadily each year, reaching over 1 billion USD by 2022. This indicates sustained business growth and successful market expansion or product sales increase. The most notable accelerations in growth occur between 2011 and 2017, where revenue nearly quadruples.
- Income (loss) from operations
- This metric shows a pronounced improvement over the analyzed timeframe. Initially, there are substantial operational losses, reaching nearly 30 million USD in losses in several early years (2006-2008). From 2011 onwards, operational income shifts into positive territory, showing continuous growth with a peak above 249 million USD in 2020, before a decline in 2022 to approximately 141 million USD. This recovery and growth imply enhanced operational efficiency, cost management, or scaling effects. The dip in 2022 might indicate emerging challenges or increased operational expenses.
- Net income (loss)
- Net income follows a broadly similar trend to operational income but with more volatility. Initially, the company reports substantial net losses from 2005 through 2010, with the largest loss exceeding 40 million USD in 2008. Beginning in 2011, net income turns positive, showing significant fluctuations, such as a notable peak exceeding 259 million USD in 2019, then declining to approximately 136.5 million USD by 2022. The variability in net income suggests influences from non-operating factors such as financing costs, taxes, or extraordinary items. Despite the fluctuations, the overall trajectory reflects an improvement in profitability as the company matures.
Balance Sheet: Assets
Abiomed Inc., selected items from assets, long-term trends
US$ in thousands
| Current assets | Total assets | |
|---|---|---|
| Mar 31, 2022 | 976,473) | 1,673,393) |
| Mar 31, 2021 | 787,965) | 1,494,359) |
| Mar 31, 2020 | 635,863) | 1,216,462) |
| Mar 31, 2019 | 677,197) | 1,054,346) |
| Mar 31, 2018 | 494,271) | 786,375) |
| Mar 31, 2017 | 326,958) | 550,414) |
| Mar 31, 2016 | 288,392) | 423,931) |
| Mar 31, 2015 | 220,139) | 338,367) |
| Mar 31, 2014 | 117,966) | 205,407) |
| Mar 31, 2013 | 116,605) | 169,999) |
| Mar 31, 2012 | 110,539) | 153,911) |
| Mar 31, 2011 | 84,737) | 131,588) |
| Mar 31, 2010 | 82,668) | 129,570) |
| Mar 31, 2009 | 88,489) | 135,958) |
| Mar 31, 2008 | 71,503) | 118,031) |
| Mar 31, 2007 | 96,382) | 136,183) |
| Mar 31, 2006 | 46,443) | 78,537) |
| Mar 31, 2005 | 55,224) | 61,061) |
Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31), 10-K (reporting date: 2016-03-31), 10-K (reporting date: 2015-03-31), 10-K (reporting date: 2014-03-31), 10-K (reporting date: 2013-03-31), 10-K (reporting date: 2012-03-31), 10-K (reporting date: 2011-03-31), 10-K (reporting date: 2010-03-31), 10-K (reporting date: 2009-03-31), 10-K (reporting date: 2008-03-31), 10-K (reporting date: 2007-03-31), 10-K (reporting date: 2006-03-31), 10-K (reporting date: 2005-03-31).
The data reveals a consistent upward trajectory in both current assets and total assets over the analyzed period, indicating ongoing growth and expansion in asset base.
- Current Assets
- Current assets increased from approximately $55.2 million in March 2005 to about $976.5 million in March 2022, demonstrating a significant expansion of around seventeen-fold over the 17-year span.
- There is a noticeable rise beginning in 2014, where current assets nearly doubled from roughly $118 million in 2014 to $220 million in 2015, followed by a continued steep increase peaking at $976 million by 2022.
- The growth trend reflects strengthening liquidity or working capital capacity, which could enable increased operational flexibility or support further business activities.
- Total Assets
- Total assets grew steadily from around $61.1 million in 2005 to $1.673 billion in 2022, indicating nearly a twenty-seven-fold increase over the period.
- A notable acceleration in asset accumulation is evident starting around 2014, paralleling the pattern observed in current assets, with total assets rising from roughly $205 million in 2014 to over $1.6 billion by 2022.
- The continuous asset growth signals ongoing investment, possible acquisitions, or capital expenditure driving overall asset base expansion.
Overall, the asset composition suggests a company that has significantly expanded its scale and capacity, with current assets maintaining a substantial proportion of total assets throughout the years, which may imply a focus on liquidity and short-term asset management alongside broader asset growth.
Balance Sheet: Liabilities and Stockholders’ Equity
Abiomed Inc., selected items from liabilities and stockholders’ equity, long-term trends
US$ in thousands
| Current liabilities | Total liabilities | Capital lease obligation | Stockholders’ equity | |
|---|---|---|---|---|
| Mar 31, 2022 | 138,457) | 170,067) | —) | 1,503,326) |
| Mar 31, 2021 | 128,969) | 164,684) | —) | 1,329,675) |
| Mar 31, 2020 | 131,885) | 150,996) | —) | 1,065,466) |
| Mar 31, 2019 | 105,998) | 117,456) | —) | 936,890) |
| Mar 31, 2018 | 84,682) | 96,851) | —) | 689,524) |
| Mar 31, 2017 | 69,617) | 98,343) | 16,338) | 452,071) |
| Mar 31, 2016 | 46,541) | 55,156) | —) | 368,775) |
| Mar 31, 2015 | 39,319) | 46,807) | —) | 291,560) |
| Mar 31, 2014 | 30,411) | 37,054) | —) | 168,353) |
| Mar 31, 2013 | 27,056) | 32,919) | —) | 137,080) |
| Mar 31, 2012 | 22,415) | 27,614) | —) | 126,297) |
| Mar 31, 2011 | 22,343) | 26,845) | —) | 104,743) |
| Mar 31, 2010 | 18,064) | 21,614) | —) | 107,956) |
| Mar 31, 2009 | 17,579) | 19,975) | —) | 115,983) |
| Mar 31, 2008 | 19,476) | 24,437) | —) | 93,594) |
| Mar 31, 2007 | 12,897) | 14,088) | —) | 122,095) |
| Mar 31, 2006 | 8,739) | 9,049) | —) | 69,488) |
| Mar 31, 2005 | 4,882) | 4,882) | —) | 56,179) |
Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31), 10-K (reporting date: 2016-03-31), 10-K (reporting date: 2015-03-31), 10-K (reporting date: 2014-03-31), 10-K (reporting date: 2013-03-31), 10-K (reporting date: 2012-03-31), 10-K (reporting date: 2011-03-31), 10-K (reporting date: 2010-03-31), 10-K (reporting date: 2009-03-31), 10-K (reporting date: 2008-03-31), 10-K (reporting date: 2007-03-31), 10-K (reporting date: 2006-03-31), 10-K (reporting date: 2005-03-31).
The analysis of the financial data reveals several key trends in liabilities and stockholders’ equity over the period examined.
- Current Liabilities
- Current liabilities have generally increased over the timeline, starting at 4,882 thousand US dollars in March 2005 and rising steadily to 138,457 thousand US dollars by March 2022. Notable increments are observed particularly after 2012, with the figure more than doubling between 2013 (27,056 thousand) and 2015 (39,319 thousand), and then continuing to increase sharply through to 2022.
- Total Liabilities
- Total liabilities show a similar upward trend from 4,882 thousand US dollars in March 2005 to 170,067 thousand US dollars by March 2022. Although the increase is substantial, the progression is somewhat irregular, with some periods showing slower growth or marginal declines. The jump in total liabilities between 2016 (55,156 thousand) and 2017 (98,343 thousand) is particularly significant.
- Capital Lease Obligation
- Capital lease obligations appear only as a discrete figure in the data set for the year ended March 2017, reported at 16,338 thousand US dollars. This suggests either a new classification or recognition of such obligations in that year or a one-time event relating to leasing commitments.
- Stockholders’ Equity
- Stockholders’ equity shows a strong and consistent upward trend throughout the period. From 56,179 thousand US dollars in March 2005, equity grows significantly, especially from 2012 onwards, reaching 1,503,326 thousand US dollars by March 2022. The data indicates marked acceleration in equity growth from 2014 onward, with the figure nearly doubling between 2016 and 2019, reflecting robust capital accumulation and potentially strong retained earnings or equity financing activities.
Overall, liabilities have increased in absolute terms but at a lesser pace compared to stockholders’ equity, which more than twentyfold increased from 2005 to 2022. The relatively rapid equity growth compared to liabilities suggests an improvement in the financial leverage position over time. The introduction or reporting of capital lease obligations in 2017 is noteworthy but does not appear to significantly impact the overall liabilities trend in subsequent years.
Cash Flow Statement
Abiomed Inc., selected items from cash flow statement, long-term trends
US$ in thousands
| 12 months ended: | Net cash provided by (used for) operating activities | Net cash (used for) provided by investing activities | Net cash provided by (used for) financing activities |
|---|---|---|---|
| Mar 31, 2022 | 285,390) | (380,990) | (2,202) |
| Mar 31, 2021 | 274,578) | (223,344) | (8,067) |
| Mar 31, 2020 | 314,920) | (125,455) | (117,715) |
| Mar 31, 2019 | 252,197) | (116,455) | (55,775) |
| Mar 31, 2018 | 192,546) | (180,762) | (9,137) |
| Mar 31, 2017 | 115,116) | (126,333) | 3,867) |
| Mar 31, 2016 | 76,795) | (57,710) | 7,160) |
| Mar 31, 2015 | 43,290) | (49,863) | 9,523) |
| Mar 31, 2014 | 23,466) | (22,272) | 9,632) |
| Mar 31, 2013 | 26,399) | (10,265) | (11,811) |
| Mar 31, 2012 | 3,634) | (17,480) | 14,680) |
| Mar 31, 2011 | 1,574) | (2,352) | 1,374) |
| Mar 31, 2010 | (7,362) | 8,818) | 979) |
| Mar 31, 2009 | (18,305) | (26,805) | 46,230) |
| Mar 31, 2008 | (28,874) | (40,905) | 2,070) |
| Mar 31, 2007 | (19,820) | 15,095) | 66,557) |
| Mar 31, 2006 | (9,339) | 7,369) | 2,093) |
| Mar 31, 2005 | (5,164) | 1,916) | 4,087) |
Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31), 10-K (reporting date: 2016-03-31), 10-K (reporting date: 2015-03-31), 10-K (reporting date: 2014-03-31), 10-K (reporting date: 2013-03-31), 10-K (reporting date: 2012-03-31), 10-K (reporting date: 2011-03-31), 10-K (reporting date: 2010-03-31), 10-K (reporting date: 2009-03-31), 10-K (reporting date: 2008-03-31), 10-K (reporting date: 2007-03-31), 10-K (reporting date: 2006-03-31), 10-K (reporting date: 2005-03-31).
- Net Cash Provided by (Used for) Operating Activities
- The net cash from operating activities exhibited a negative trend from 2005 through 2008, starting with -5,164 thousand USD in 2005 and deteriorating to -28,874 thousand USD in 2008. This period indicates operational cash outflows. Beginning in 2009, there was a shift to positive cash flows, with values increasing steadily from 15,574 thousand USD in 2011 to a peak of 314,920 thousand USD in 2020. Although there was a decline after 2020, the operating cash flow remained robust at 285,390 thousand USD in 2022, suggesting improved operational efficiency and cash generation over time.
- Net Cash (Used for) Provided by Investing Activities
- Investing activities cash flow was positive in the early years, peaking at 15,095 thousand USD in 2007. However, there was a significant shift beginning in 2008, where cash flows became negative and remained so thereafter. The outflows increased substantially from -23,352 thousand USD in 2011 to an all-time low of -380,990 thousand USD in 2022, reflecting heavy investment or asset acquisition activities. The continual increase in negative cash flows for investing activities signals aggressive capital expenditure or investments in long-term assets during the last decade.
- Net Cash Provided by (Used for) Financing Activities
- Financing cash flows were volatile across the observed period, starting with inflows in the low thousands from 2005 through 2007, including a notable spike to 66,557 thousand USD in 2007. Following 2008, the activity fluctuated with moderate positive and negative values. After peaking in 2009 at 46,230 thousand USD, there was a general downward trend with notable negative cash flows recorded in 2019 (-55,775 thousand USD) and 2020 (-117,715 thousand USD), indicating repayments or reductions in financing activities. The recent years show relatively low inflows or small outflows, suggesting a more balanced or conservative approach to financing.
Per Share Data
Abiomed Inc., selected data per share, long-term trends
US$
| 12 months ended: | Basic earnings per share 1 | Diluted earnings per share 2 | Dividend per share 3 |
|---|---|---|---|
| Mar 31, 2022 | 3.00 | 2.98 | 0.00 |
| Mar 31, 2021 | 5.00 | 4.94 | 0.00 |
| Mar 31, 2020 | 4.49 | 4.43 | 0.00 |
| Mar 31, 2019 | 5.77 | 5.61 | 0.00 |
| Mar 31, 2018 | 2.54 | 2.45 | 0.00 |
| Mar 31, 2017 | 1.21 | 1.17 | 0.00 |
| Mar 31, 2016 | 0.90 | 0.85 | 0.00 |
| Mar 31, 2015 | 2.80 | 2.65 | 0.00 |
| Mar 31, 2014 | 0.19 | 0.18 | 0.00 |
| Mar 31, 2013 | 0.38 | 0.37 | 0.00 |
| Mar 31, 2012 | 0.04 | 0.04 | 0.00 |
| Mar 31, 2011 | -0.32 | -0.32 | 0.00 |
| Mar 31, 2010 | -0.52 | -0.52 | 0.00 |
| Mar 31, 2009 | -0.91 | -0.91 | 0.00 |
| Mar 31, 2008 | -1.26 | -1.26 | 0.00 |
| Mar 31, 2007 | -1.03 | -1.03 | 0.00 |
| Mar 31, 2006 | -1.15 | -1.15 | 0.00 |
| Mar 31, 2005 | -0.11 | -0.11 | 0.00 |
Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31), 10-K (reporting date: 2016-03-31), 10-K (reporting date: 2015-03-31), 10-K (reporting date: 2014-03-31), 10-K (reporting date: 2013-03-31), 10-K (reporting date: 2012-03-31), 10-K (reporting date: 2011-03-31), 10-K (reporting date: 2010-03-31), 10-K (reporting date: 2009-03-31), 10-K (reporting date: 2008-03-31), 10-K (reporting date: 2007-03-31), 10-K (reporting date: 2006-03-31), 10-K (reporting date: 2005-03-31).
1, 2, 3 Data adjusted for splits and stock dividends.
- Basic Earnings Per Share (EPS) Trend
- The basic earnings per share show a negative trend from 2005 through 2008, starting at -0.11 US$ in 2005 and reaching a low of -1.26 US$ in 2008. Following this period, there is a steady improvement, crossing into positive territory by 2012 at 0.04 US$. From 2012 onward, the EPS generally exhibits growth with some fluctuations, peaking at 5.77 US$ in 2019. After this peak, EPS decreases somewhat but remains positive through 2022, ending at 3 US$.
- Diluted Earnings Per Share (EPS) Trend
- The diluted EPS mirrors the pattern observed in basic EPS closely. It starts negatively at -0.11 US$ in 2005, decreases to -1.26 US$ in 2008, and then gradually improves. Diluted EPS becomes positive by 2012 at 0.04 US$. The value continues to rise, reaching its highest point at 5.61 US$ in 2019, before declining to 2.98 US$ in 2022. The differences between basic and diluted EPS across all years are minimal, indicating a small dilutive effect.
- Dividend Per Share
- No dividend payments were recorded throughout the entire period presented, indicating the absence of dividend distribution to shareholders from 2005 to 2022.